Literature DB >> 1622188

Use of high-dose fluconazole as salvage therapy for cryptococcal meningitis in patients with AIDS.

A J Berry1, M G Rinaldi, J R Graybill.   

Abstract

Eight patients with AIDS were treated orally with 800 mg of fluconazole daily for cryptococcal meningitis for a mean duration of 4.5 months. Previous antifungal treatment had failed for all of the patients. No major toxicity was observed. Three patients died from cryptococcal infection. High-dose fluconazole may be effective salvage therapy for cryptococcal meningitis.

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1622188      PMCID： PMC190584          DOI： 10.1128/AAC.36.3.690

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  10 in total

1.  Fluconazole penetration into cerebrospinal fluid: implications for treating fungal infections of the central nervous system.

Authors:  C A Arndt; T J Walsh; C L McCully; F M Balis; P A Pizzo; D G Poplack
Journal:  J Infect Dis       Date:  1988-01       Impact factor: 5.226

2.  Fluconazole compared with amphotericin B plus flucytosine for cryptococcal meningitis in AIDS. A randomized trial.

Authors:  R A Larsen; M A Leal; L S Chan
Journal:  Ann Intern Med       Date:  1990-08-01       Impact factor: 25.391

3.  Maintenance amphotericin B for cryptococcal meningitis in the acquired immunodeficiency syndrome (AIDS).

Authors:  A Zuger; M Schuster; M S Simberkoff; J J Rahal; R S Holzman
Journal:  Ann Intern Med       Date:  1988-10-01       Impact factor: 25.391

4.  Infections with Cryptococcus neoformans in the acquired immunodeficiency syndrome.

Authors:  S L Chuck; M A Sande
Journal:  N Engl J Med       Date:  1989-09-21       Impact factor: 91.245

5.  Oral fluconazole as suppressive therapy of disseminated cryptococcosis in patients with acquired immunodeficiency syndrome.

Authors:  A M Sugar; C Saunders
Journal:  Am J Med       Date:  1988-10       Impact factor: 4.965

Review 6.  Pharmacokinetics and tissue penetration of fluconazole in humans.

Authors:  K W Brammer; P R Farrow; J K Faulkner
Journal:  Rev Infect Dis       Date:  1990 Mar-Apr

7.  Cryptococcosis in the acquired immunodeficiency syndrome.

Authors:  J A Kovacs; A A Kovacs; M Polis; W C Wright; V J Gill; C U Tuazon; E P Gelmann; H C Lane; R Longfield; G Overturf
Journal:  Ann Intern Med       Date:  1985-10       Impact factor: 25.391

8.  Cryptococcal meningitis in patients with AIDS.

Authors:  W E Dismukes
Journal:  J Infect Dis       Date:  1988-04       Impact factor: 5.226

9.  Cryptococcal disease in patients with the acquired immunodeficiency syndrome. Diagnostic features and outcome of treatment.

Authors:  A Zuger; E Louie; R S Holzman; M S Simberkoff; J J Rahal
Journal:  Ann Intern Med       Date:  1986-02       Impact factor: 25.391

10.  A placebo-controlled trial of maintenance therapy with fluconazole after treatment of cryptococcal meningitis in the acquired immunodeficiency syndrome. California Collaborative Treatment Group.

Authors:  S A Bozzette; R A Larsen; J Chiu; M A Leal; J Jacobsen; P Rothman; P Robinson; G Gilbert; J A McCutchan; J Tilles
Journal:  N Engl J Med       Date:  1991-02-28       Impact factor: 91.245
  10 in total
  18 in total

1.  Clinical pharmacokinetics of fluconazole in superficial and systemic mycoses.

Authors:  D Debruyne
Journal:  Clin Pharmacokinet       Date:  1997-07       Impact factor: 6.447

Review 2.  Resistance of Candida species to fluconazole.

Authors:  J H Rex; M G Rinaldi; M A Pfaller
Journal:  Antimicrob Agents Chemother       Date:  1995-01       Impact factor: 5.191

3.  Phase I evaluation of the safety and pharmacokinetics of murine-derived anticryptococcal antibody 18B7 in subjects with treated cryptococcal meningitis.

Authors:  Robert A Larsen; Peter G Pappas; John Perfect; Judith A Aberg; Arturo Casadevall; Gretchen A Cloud; Robert James; Scott Filler; William E Dismukes
Journal:  Antimicrob Agents Chemother       Date:  2005-03       Impact factor: 5.191

4.  Effect of fluconazole on fungicidal activity of flucytosine in murine cryptococcal meningitis.

Authors:  R A Larsen; M Bauer; J M Weiner; D M Diamond; M E Leal; J C Ding; M G Rinaldi; J R Graybill
Journal:  Antimicrob Agents Chemother       Date:  1996-09       Impact factor: 5.191

5.  Effect of severity of meningitis on fungicidal activity of flucytosine combined with fluconazole in a murine model of cryptococcal meningitis.

Authors:  J C Ding; M Bauer; D M Diamond; M A Leal; D Johnson; B K Williams; A M Thomas; L Najvar; J R Graybill; R A Larsen
Journal:  Antimicrob Agents Chemother       Date:  1997-07       Impact factor: 5.191

6.  Fluconazole distribution to the brain: a crossover study in freely-moving rats using in vivo microdialysis.

Authors:  H Yang; Q Wang; W F Elmquist
Journal:  Pharm Res       Date:  1996-10       Impact factor: 4.200

7.  Amphotericin B colloidal dispersion combined with flucytosine with or without fluconazole for treatment of murine cryptococcal meningitis.

Authors:  D M Diamond; M Bauer; B E Daniel; M A Leal; D Johnson; B K Williams; A M Thomas; J C Ding; L Najvar; J R Graybill; R A Larsen
Journal:  Antimicrob Agents Chemother       Date:  1998-03       Impact factor: 5.191

8.  Pharmacokinetics of 18F-labeled fluconazole in healthy human subjects by positron emission tomography.

Authors:  A J Fischman; N M Alpert; E Livni; S Ray; I Sinclair; R J Callahan; J A Correia; D Webb; H W Strauss; R H Rubin
Journal:  Antimicrob Agents Chemother       Date:  1993-06       Impact factor: 5.191

Review 9.  Current and emerging azole antifungal agents.

Authors:  D J Sheehan; C A Hitchcock; C M Sibley
Journal:  Clin Microbiol Rev       Date:  1999-01       Impact factor: 26.132

Review 10.  Clinical pharmacokinetics of fluconazole.

Authors:  D Debruyne; J P Ryckelynck
Journal:  Clin Pharmacokinet       Date:  1993-01       Impact factor: 6.447
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.